Track record · closed signal

Pfizer Inc. (PFE) — closed signal from August 31, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 29, 2025.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted
$24.33 Published $26.78 Target $25.74 Window close $27.21 Peak
$23.66 – $24.14Entry zone — fair-value band
$24.33Published — price the day we called it
$26.78Target — the price the thesis aimed for
$27.21Peak — highest point inside the window, not a realized return
$25.74Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price
$27.21
peak on October 3, 2025 — not a realized return
Peak gain
+11.8%
peak, from the publication price
Window close
$25.74
end-of-window price, context only
Days to target
—
Window
August 31, 2025 – November 29, 2025

The thesis — published August 31, 2025

Predicted growth
+12%
over the measurement window
Target price
$26.78
the price the thesis aimed for
Entry zone
$23.66 – $24.14
the fair-value band we waited for
Price at publication
$24.33
published August 31, 2025
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Pfizer shares look washed out, which can draw buyers back. The FDA just cleared an updated COVID-19 shot for higher-risk people, likely adding some sales and attention. Big biotech is back in focus. Over the next 1-3 months, consider starting near $24.50-$25.00 and add slowly if the trend firms as new drugs move ahead and cash flow steadies. Also watch for calmer swings and more steady up days.

Primary drivers

  • New FDA approval for an updated COVID-19 shot could lift sales and attention
  • Stock looks beaten down; buyers may return after a long period of weakness
  • Large biotech companies are back in favor, drawing fresh investor interest
  • Look for signs the trend turns up gradually, not just a quick bounce

How it played out

PFE: price cleared the target, then gave back ground

Lyra published PFE at $24.33 on 2025-08-31 with expected growth of 12%. The thesis pointed to an updated COVID-19 shot cleared by the FDA for higher-risk people, a beaten-down stock that might draw buyers back, fresh interest in large biotech, and a gradual turn higher.

Inside the window, PFE peaked at $27.21 on 2025-10-03, above the $26.78 target. The data did not give a target-hit day. The peak gain was 11.8%. By 2025-11-29, it ended at $25.74. The thesis partially played out.

What happened during the window

On September 30, 2025, Pfizer and President Donald Trump announced a drug-pricing deal tied to Medicaid pricing and a government purchasing platform. Pfizer also said it would spend $70 billion on research and development and capital projects.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals